Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder-Reference-Cited by-同舟云学术

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Published:2022-08 Issue:2 Volume:82 Page:212-222
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Szabados Bernadett,Kockx Mark,Assaf Zoe June,van Dam Pieter-Jan,Rodriguez-Vida Alejo,Duran Ignacio,Crabb Simon J.,Van Der Heijden Michiel S.,Pous Albert Font,Gravis Gwenaelle,Herranz Urbano Anido,Protheroe Andrew,Ravaud Alain,Maillet Denis,Mendez Maria Jose,Suarez Cristina,Linch Mark,Prendergast Aaron,Tyson Charlotte,Stanoeva Diana,Daelemans Sofie,Rombouts Miche,Mariathasan Sanjeev,Tea Joy S.,Mousa Kelly,Sharma Shruti,Aleshin Alexey,Banchereau Romain,Castellano Daniel,Powles Thomas

Publisher

Elsevier BV

Subject

Urology

Reference26 articles.

1. Perioperative treatment and radical cystectomy for bladder cancer—a population based trend analysis of 10,338 patients in the Netherlands;Hermans;Eur J Cancer,2016

2. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy;Galsky;J Clin Oncol,2011

3. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium;Shariat;J Urol,2006

4. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial;Powles;Nat Med,2019

5. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study;Necchi;J Clin Oncol,2018

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial;Nature Cancer;2024-09-10

2. Variation in cystectomy pathology reporting practice—results from an international survey of 212 pathologists;Virchows Archiv;2024-09-07

3. First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer;Journal of Clinical Oncology;2024-09-06

4. Tumor-informed circulating tumor DNA in urothelial carcinoma: a promising novel biomarker;Current Opinion in Urology;2024-09-04

5. Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis;The French Journal of Urology;2024-09